Project Grant R21CA309056
- The National Institute of Neurological Disorders and Stroke awarded the University of Utah $2,126,986 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a decentralized trial of evidence-based pain care in rural communities. The award funds the Better Pain Care with Telehealth & Technology (BP-2) trial, a hybrid II effectiveness-implementation study designed to address how digital health strategies can improve pain management in rural...
- The National Institute of Neurological Disorders and Stroke awarded the University of Rochester $2,197,287 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a Phase III confirmatory clinical trial of daily, wireless, home-based transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN). The trial will evaluate TENS efficacy in relieving neuropathic pain in cancer patients who have developed CIPN—a common...
- The National Institute of Neurological Disorders and Stroke awarded Yale University $4.17 million on August 25, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a biopsychosocial model for peripheral artery disease pain management that integrates vascular interventions with psychological and behavioral assessment. The project develops novel MRI protocols to evaluate blood flow, muscle and nerve microstructure, and metabolism in patients with peripheral artery...
- The National Institute on Drug Abuse awarded the University of Utah $162,200 on October 10, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to characterize pain embodiment and its relationship to opioid misuse risk in chronic pain using neuroimaging. The award funds a five-year research project through September 30, 2030, performed in Salt Lake City, Utah. The research will employ resting-state functional magnetic resonance imaging to study pain embodiment—the tendency...
- The National Institute of Neurological Disorders and Stroke awarded The Ohio State University $10.115 million on September 12, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a prospective observational study modeling diverse experiences and longitudinal trajectories of acute pain in emergency department settings. The study—titled MODEL-PAIN (MOdeling Diverse Experiences and Longitudinal trajectories of pain)—will enroll 2,400 emergency department patients and...
- The National Institute of Neurological Disorders and Stroke awarded a cooperative agreement totaling $7.587 million to the University of Pittsburgh on September 19, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds research to determine the evolution of whole-person pain characteristics in chronic low back pain (CLBP) individuals and to validate, refine, and augment CLBP models by integrating longitudinal data, chronic overlapping pain conditions (COPCs),...
- Summary The University of Washington received a $4.45M Cooperative Agreement from the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279) effective August 1, 2025 through July 31, 2028. The project adapts and implements a Nurse Care Management (NCM) model designed to address chronic pain in rural populations through an evidence-based, multi-component intervention. The NCM model integrates care coordination, cognitive behavioral...
- The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health under the Department of Health and Human Services, awarded the University of Maryland, Baltimore $4.929 million on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate a multi-omic, psychosocial, and environmental model of individual differences in pain and placebo responses. The project investigates chronic pain conditions, particularly...
- The National Institute of Neurological Disorders and Stroke awarded a cooperative agreement worth $4,041,667 to Cincinnati Children's Hospital Medical Center on September 19, 2025, to conduct research on the biopsychosocial determinants of pediatric-onset chronic musculoskeletal pain. The research employs a mixed retrospective-prospective cohort study design to enroll 600 adolescents and young adults ages 16–26, including 400 with primary chronic musculoskeletal pain or chronic musculoskeletal...
- The National Institute of Neurological Disorders and Stroke awarded $462,000 to Icahn School of Medicine at Mount Sinai on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and conduct a proof-of-concept study of a videoconference-based hypnosis intervention for pain management in women with metastatic breast cancer. The research addresses pain management in the population of over 168,000 women living with metastatic breast cancer in the United...
The National Institute of Neurological Disorders and Stroke awarded the University of Tennessee $475,375 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and pilot a family-based pain intervention for Appalachian breast cancer patients experiencing treatment-related pain during adjuvant endocrine therapy. The Conquering Pain Together (CPT) intervention addresses pain discontinuation as a primary driver of therapy non-adherence in rural Appalachia, where pharmacological pain management carries elevated risk in opioid-affected communities. The project recognizes pain as a dyadic experience in which caregiver psychosocial distress predicts worse patient outcomes. CPT harnesses family and faith as core Appalachian strengths to manage pain relationally, mitigate dyadic psychological distress, and connect participants to community resources through flexible delivery and warm hand-offs. The award funds two specific aims over the performance period of September 1, 2026 through August 31, 2028. The first aim adapts the CPT protocol through iterative, community-engaged interviews with 15 Appalachian breast cancer dyads and five health professionals to ensure cultural alignment with religious traditions and focus on cancer-specific distress. The second aim pilots the adapted CPT in a single-arm feasibility trial with 30 dyads, using purposive sampling to achieve 50 percent rural enrollment and establish benchmarks for recruitment, acceptability, and protocol adherence. Work is performed in Knoxville, Tennessee. The assistance type is a Project Grant, classified as R21 funding.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $475.4k | 9/1/26 |